by bnn-news 02/25/2021
After a drop that lasted several weeks the epidemiological situation in Latvia has become worse again, because the number of Covid-19 infection cases in a seven-day period is on a rise, said epidemiologist of the State Disease Prevention and Monitoring Centre Jurijs Perevoščikovs at a meeting of the government.
Many host proteins play a role in the life cycle of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and some are required for viral replication and translation. There are efforts toward finding drugs that target viral proteins, but a complementary approach is to target these required host proteins. White et al. explored the antiviral activity of the cyclic depsipeptide drug plitidepsin, which targets the hosts cell's translational machinery (see the Perspective by Wong and Damania). The authors show that in cells, the drug is substantially more potent than remdesivir against SARS-CoV-2, with limited cellular toxicity. Prophylactic treatment protected mice against SARS-CoV-2 infection, so further investigation of plitidepsin as a therapeutic is warranted. Science , this issue p. ; see also p.  Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins interact with the eukaryotic translation machinery, and inhibitors of translation have potent antiviral effects. We found that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5, with limited toxicity in cell culture. Through the use of a drug-resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A). We demonstrate the in vivo efficacy of plitidepsin treatment in two mouse models of SARS-CoV-2 infection with a reduction of viral replication in the lungs by two orders of magnitude using prophylactic treatment. Our results indicate that plitidepsin is a promising therapeutic candidate for COVID-19. : /lookup/doi/10.1126/science.abf4058 : /lookup/doi/10.1126/science.abg6837
The President of Paraguay, Mario Abdo Benítez, said this Thursday during his speech at the V Extraordinary Summit of the Forum for the Progress of South America (PROSUR), that the solidarity of developed countries is essential for equitable access to vaccines against COVID-19. In the framework of the virtual meeting, the Paraguayan president expressed his
The biopharmaceutical company Nasus Pharma created the nasal powder inhaler called Taffix and it is established as a complementary element to the use of the mask and not a substitute for it. It was approved for use in Israel and indicated as a protective mechanical barrier against allergens and viruses, such as SARS-CoV-2, which causes